Pentwater Capital Management LP 13D and 13G filings for Poseida Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-13 4:05 pm Sale |
2025-01-08 | 13D | Poseida Therapeutics, Inc. PSTX |
Pentwater Capital Management LP | 0 0.000% |
-8,625,000 (Position Closed) |
Filing |
| 2024-11-27 7:01 pm Purchase |
2024-11-25 | 13D | Poseida Therapeutics, Inc. PSTX |
Pentwater Capital Management LP | 8,625,000 8.800% |
3,657,773 (+73.64%) |
Filing |
| 2022-04-25 4:30 pm Unchanged |
2022-04-22 | 13D | Poseida Therapeutics, Inc. PSTX |
Pentwater Capital Management LP | 4,967,227 7.940% |
0 (Unchanged) |
Filing |
| 2020-12-28 4:05 pm Purchase |
2020-12-16 | 13D | Poseida Therapeutics, Inc. PSTX |
Pentwater Capital Management LP | 4,967,227 8.030% |
4,967,227 (New Position) |
Filing |